Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study retrospectively analyzed the outcomes of 61 pediatric patients with inborn errors of immunity (IEI) who underwent hematopoietic stem cell transplantation (HSCT) between 2011 and 2023. Patients were categorized into primary immunodeficiency disorders (PIDD), primary immune dysregulation disorders (PIRD), and congenital defects of phagocyte number or function (CDP). Median ages at diagnosis and HSCT were 9 and 30 months, respectively. With a median follow-up of 51 months, the overall survival (OS) was 70%, with a 100-day post-transplant OS of 80%. Transplant-related mortality (TRM) was 29%, with rates of 42%, 22.5%, and 27% for PIRD, PIDD, and CDP, respectively. This study highlights the importance of early diagnosis and HSCT in improving survival for IEI patients, while also emphasizing the need for continuous improvements in transplant protocols to minimize TRM and enhance quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/sji.13431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asynchronous Development of B-cell and T-cell Post-transplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Patient.
J Pediatr Hematol Oncol
September 2025
Division of Pediatric Hematology-Oncology, Mayo Clinic Children's, Rochester, MN.
Post-transplant lymphoproliferative disorder is a rare and serious complication of organ and stem cell transplant secondary to immunosuppressive therapies, most commonly of monomorphic B-cell subtype. Here we describe the first reported case of a pediatric heart transplant patient who developed both monomorphic B-cell and nondestructive PTLD with plasmacytic hyperplasia followed by an unrelated case of monomorphic T-cell and nondestructive PTLD with plasmacytic hyperplasia, which later relapsed. We detail the patient's risk factors for development of PTLD and her successful treatment regimens.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies.
Blood Adv
September 2025
AP-HP, Hôpital Saint Louis and University of Paris, INSERM U944 and THEMA insitute, Paris, France.
Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.
View Article and Find Full Text PDFDiagnosis and Management of a Child With Primary Pancreatic Neuroblastoma: Case Report of a Common Malignancy at a Rare Site.
J Pediatr Hematol Oncol
September 2025
Nuclear Medicine, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Pediatric pancreatic neuroblastoma is a rare cancer in children, with only limited cases available in the literature. We report a case of a 4-year-old girl diagnosed with high-risk pancreatic neuroblastoma. The girl was treated with induction chemotherapy followed by autologous stem cell transplant and maintenance with 13-cis-retinoic acid.
View Article and Find Full Text PDFInhalation of Mesenchymal-Stem-Cell-Derived Nanovesicles Delivering Catalase Enhances the Treatment for Acute Lung Injury.
ACS Nano
September 2025
Department of Emergency and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou 215124, China.
Acute lung injury (ALI) is characterized by the excessive accumulation of reactive oxygen species (ROS), which triggers a severe inflammatory cascade and the destruction of the alveolar-capillary barrier, leading to respiratory failure and life-threatening outcomes. Considering the limitations and adverse effects associated with current therapeutic interventions, developing effective and safe strategies that target the complex pathophysiological mechanisms of ALI is crucial for improving patient outcomes. Herein, we developed an inhalable, multifunctional nanotherapeutic (MSCNVs@CAT) by encapsulating catalase (CAT) in mesenchymal-stem-cell-derived nanovesicles (MSCNVs).
View Article and Find Full Text PDFThe Number of CD34 Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure.
Clin Transplant
September 2025
Centro De Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico.